Close

MPyVgp5

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

New MPyV virions are assembled in the nucleus in dense local aggregations known as virus factories. Capsid proteins, produced in the cytoplasm of the host cell, enter the nucleus as assembled capsomers consisting of pentameric VP1 associated with VP2 or VP3. Nuclear localization sequences consistent with karyopherin interactions have been identified in capsid protein sequences, facilitating their transit through nuclear pores. Once inside the nucleus they assemble into mature capsids containing a copy of the viral genome, although the exact mechanism of encapsidation is not well understood. Filamentous or tubular structures representing polymerized VP1 have been observed in the nuclei of infected cells as intermediates in the assembly process from which mature virions are produced.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • Target Species:
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC0710 Mouse anti-MPyVgp5 T cell receptor (C3K), pCDTCR1 MPyV1 C3K Mouse HALNVVHDW H2-Q9 Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.